Cardiff Lexington Signs LOI to Acquire Musculoskeletal Platform for Up to $104M
CDIX has more than doubled off its 52-week low of $0.116.
Summary
Cardiff Lexington announced a non-binding letter of intent to acquire a multi-location musculoskeletal healthcare platform for up to $104 million. The deal includes $30 million cash at closing, $10 million in unsecured notes, preferred equity giving sellers 35% ownership, and up to $12 million in earnouts tied to EBITDA targets. The target operates in multiple states and would significantly expand Cardiff's orthopedic and spine care footprint. Financing is not yet secured, and the LOI is subject to due diligence and definitive agreements, with a projected closing date of November 16, 2026. This follows a Q2 2026 filing showing a going concern warning and only $218K in cash, making the financing risk a key concern. The 45-day exclusivity period and earnout structure align seller interests with long-term growth.
At the time of this announcement, CDIX was trading at $0.60 on OTC in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.12 to $180.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.